Suppr超能文献

患者对局限性前列腺癌的观察等待/主动监测的看法。

Patient perspective on watchful waiting/active surveillance for localized prostate cancer.

机构信息

Department of Family Medicine and Public Health Sciences, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.

出版信息

J Am Board Fam Med. 2012 Nov-Dec;25(6):763-70. doi: 10.3122/jabfm.2012.06.120128.

Abstract

OBJECTIVE

To describe prostate cancer treatment decision making, focusing on knowledge and attitudes toward observation, known as watchful waiting (WW) or active surveillance (AS), and reasons for not choosing WW/AS.

METHODS

Semistructured in-person interviews were conducted with 21 men (14 black; 7 white) with recently diagnosed localized prostate cancer.

RESULTS

All cancers were detected by prostate-specific antigen screening; 14 men had low-risk disease. Nineteen chose surgery or radiation treatment. The majority wanted to "get rid of" or "cure" the cancer by undergoing aggressive therapy, even with awareness of the potential for significant side effects. Most men seemed unaware of the uncertainty/controversies that aggressive treatment may not cure their cancer or improve their survival. Limited knowledge about WW/AS was common, and few remembered WW/AS being presented as a viable option. Rather, many men perceived it as "doing nothing." Some men, who initially were inclined toward WW/AS, yielded to pressure from family, physicians, or both to choose aggressive treatment. Lack of physician support was a significant barrier to WW/AS.

CONCLUSIONS

The observational strategy (WW/AS) was not viewed as a reasonable approach, even for those with low-risk cancer. The desire for aggressive therapy may reflect the complex psychology associated with receiving a diagnosis of cancer and the limited supportive counseling received. Further efforts to better understand and educate patients and physicians may help men make informed and appropriate treatment decisions to maximize quality of life without compromising survival.

摘要

目的

描述前列腺癌治疗决策,重点关注对观察(称为观察等待或主动监测)的了解和态度,以及不选择观察等待/主动监测的原因。

方法

对 21 名最近被诊断为局限性前列腺癌的男性(14 名黑人;7 名白人)进行半结构化的面对面访谈。

结果

所有癌症均通过前列腺特异性抗原筛查检测到;14 名男性患有低危疾病。19 人选择手术或放射治疗。大多数人希望通过积极的治疗“摆脱”或“治愈”癌症,即使他们意识到可能有严重的副作用。大多数男性似乎没有意识到积极治疗可能无法治愈他们的癌症或提高他们的生存率的不确定性/争议。对观察等待/主动监测的了解有限,很少有人记得观察等待/主动监测被提出作为一种可行的选择。相反,许多男性认为这是“无所作为”。一些最初倾向于观察等待/主动监测的男性屈服于来自家庭、医生或两者的压力,选择了积极的治疗。缺乏医生的支持是选择观察等待/主动监测的一个重大障碍。

结论

即使对于低危癌症患者,观察策略(观察等待/主动监测)也不被视为合理的方法。对积极治疗的渴望可能反映了与诊断癌症相关的复杂心理以及接受的有限支持性咨询。进一步努力更好地了解和教育患者和医生可能有助于男性做出明智和适当的治疗决策,在不影响生存的情况下最大限度地提高生活质量。

相似文献

1
Patient perspective on watchful waiting/active surveillance for localized prostate cancer.
J Am Board Fam Med. 2012 Nov-Dec;25(6):763-70. doi: 10.3122/jabfm.2012.06.120128.
2
Racial Differences in Treatment Decision-Making for Men with Clinically Localized Prostate Cancer: a Population-Based Study.
J Racial Ethn Health Disparities. 2016 Mar;3(1):35-45. doi: 10.1007/s40615-015-0109-8. Epub 2015 May 5.
3
Men's perspectives on selecting their prostate cancer treatment.
J Natl Med Assoc. 2011 Jun;103(6):468-78. doi: 10.1016/s0027-9684(15)30359-x.
4
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Eur Urol. 2017 Dec;72(6):899-907. doi: 10.1016/j.eururo.2017.07.018. Epub 2017 Aug 23.
5
Patient Knowledge and Qualities of Treatment Decisions for Localized Prostate Cancer.
J Am Board Fam Med. 2017 May-Jun;30(3):288-297. doi: 10.3122/jabfm.2017.03.160298.
6
Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
Fam Pract. 2017 Feb;34(1):90-97. doi: 10.1093/fampra/cmw123. Epub 2016 Dec 29.
7
The psychological impact of being on a monitoring pathway for localised prostate cancer: A UK-wide mixed methods study.
Psychooncology. 2019 Jul;28(7):1567-1575. doi: 10.1002/pon.5133. Epub 2019 Jun 10.
9
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Eur Urol. 2017 Oct;72(4):534-541. doi: 10.1016/j.eururo.2016.10.031. Epub 2016 Nov 2.
10
Racial Disparities in Active Surveillance for Prostate Cancer.
J Urol. 2017 Feb;197(2):342-349. doi: 10.1016/j.juro.2016.08.104. Epub 2016 Sep 3.

引用本文的文献

2
A Qualitative Exploration of Factors Influencing Prostate Cancer Adjustment Among Older Adults: A Social Ecological Model.
Am J Mens Health. 2025 Mar-Apr;19(2):15579883251315177. doi: 10.1177/15579883251315177. Epub 2025 Mar 12.
3
Exploring the potential of single-metals (Cu, Ni, Zn) decorated AlN nanostructures as sensors for flutamide anticancer drug.
Heliyon. 2023 Oct 11;9(10):e20682. doi: 10.1016/j.heliyon.2023.e20682. eCollection 2023 Oct.
5
Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
Prostate. 2023 May;83(6):498-515. doi: 10.1002/pros.24493. Epub 2023 Feb 22.
7
Risk of progression following a negative biopsy in prostate cancer active surveillance.
Prostate Cancer Prostatic Dis. 2023 Jun;26(2):403-409. doi: 10.1038/s41391-022-00582-x. Epub 2022 Aug 25.
10
Primary Care Providers' Perceptions About Participating in Low-Risk Prostate Cancer Treatment Decisions.
J Gen Intern Med. 2021 Feb;36(2):447-454. doi: 10.1007/s11606-020-06318-8. Epub 2020 Oct 29.

本文引用的文献

1
Men's perspectives on selecting their prostate cancer treatment.
J Natl Med Assoc. 2011 Jun;103(6):468-78. doi: 10.1016/s0027-9684(15)30359-x.
2
The effect of race and rural residence on prostate cancer treatment choice among men in Georgia.
Urology. 2011 Mar;77(3):581-7. doi: 10.1016/j.urology.2010.10.020.
3
Quality of life among men with prostate cancer in rural Georgia.
Urology. 2011 Apr;77(4):927-33. doi: 10.1016/j.urology.2010.12.027. Epub 2011 Feb 18.
4
Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.
Urology. 2011 Mar;77(3):588-91. doi: 10.1016/j.urology.2010.10.039. Epub 2011 Jan 7.
5
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.
7
Overdiagnosis in cancer.
J Natl Cancer Inst. 2010 May 5;102(9):605-13. doi: 10.1093/jnci/djq099. Epub 2010 Apr 22.
8
NCCN clinical practice guidelines in oncology: prostate cancer.
J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. doi: 10.6004/jnccn.2010.0012.
9
Time trends and local variation in primary treatment of localized prostate cancer.
J Clin Oncol. 2010 Mar 1;28(7):1117-23. doi: 10.1200/JCO.2009.26.0133. Epub 2010 Feb 1.
10
Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.
Urology. 2009 Dec;74(6):1296-302. doi: 10.1016/j.urology.2009.02.058.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验